F. Toulemonde

发表

Haemorrhages and anticoagulants the responsibility of the patient

F. Toulemonde, 1994 .

In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.

F. Bonini, C. Doutremépuich, R. Quilichini, 1985, Seminars in thrombosis and hemostasis.

Treatment of Heparin-Associated Thrombocytopenia and Thrombosis with Low Molecular Weight Heparin (CY 216)

Y. Gruel, C. Guérois, J. Leroy, 1985, Seminars in thrombosis and hemostasis.

[A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study].

J. Bassand, D. Didier, R. Faivre, 1988, Presse medicale.

[Monitoring of heparin in the treatment of deep venous thrombosis. An obsolete question?].

A. Kher, F. Toulemonde, 1995, Annales de cardiologie et d'angeiologie.

[Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)].

R. Khalil, L. Milandre, A. Elias, 1990, La Revue de medecine interne.

SUBCUTANEOUS ADMINISTRATION OF A LOW MOLECULAR WEIGHT HEPARIN (CY 222) COMPARED WITH SUBCUTANEOUS ADMINISTRATION OF STANDARD HEPARIN IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS

J. Bassand, R. Faivre, J. Maurat, 1987, Thrombosis and Haemostasis.

Changes in plasma fibrin degradation products as a marker of thrombus evolution in patients with deep vein thrombosis.

J. Soria, C. Soria, J. Bassand, 1988, Thrombosis research.

[First results of sequential treatment of acute vascular obstruction with plasminogen-streptokinase combination].

V. Kakkar, A. Malavaud, F. Toulemonde, 1977, Therapie.

Influence of Heparin and a Low Molecular Weight Heparin Fraction of the Leukocytes in an Experimental Venous Thrombosis Model

M. Anne, C. Doutremépuich, F. Doutremepuich, 1987, Journal of leukocyte biology.

Optimal Duration for Prophylaxis of Deep Vein Thrombosis: The New Focus?

A. Kher, F. Toulemonde, 1996 .

Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis.

P. Gaffney, C. Doutremépuich, N. Marsh, 1983, Thrombosis research.

Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222).

C. Vergnes, G. Janvier, S. Winnock, 1987, Haemostasis.

Low Molecular Weight Heparin (CY 216) Does Not Cross the Placenta During the Third Trimester of Pregnancy

F. Daffos, F. Forestier, M. Rainaut, 1987, Thrombosis and Haemostasis.

Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis.

C. Doutremépuich, F. Toulemonde, B. Bayrou, 1987, Haemostasis.

Laboratory control of heparin and heparin fragment treatment: an experimental study.

C. Doutremépuich, M. Guyot, F. Doutremepuich, 1989, Seminars in Thrombosis and Hemostasis.

Role of bone marrow in the development of thrombosis. A study of the curative and prophylactic action of heparin and heparin fragment (CY 222).

A. Massé, C. Doutremépuich, M. Guyot, 1989, Thrombosis research.

What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment?

M. Anne, C. Doutremépuich, F. Doutremepuich, 1987, Thrombosis research.

Are molecular weight and anti-Xa activity sufficient to predict the antithrombotic power of heparin fractions.

C. Doutremépuich, F. Toulemonde, F. Bousquet, 1986, Thrombosis research.

Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions.

A. Bezeaud, M. Kitzis, B. Andréassian, 1982, Thrombosis research.

The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus.

C. Doutremépuich, F. Doutremepuich, O. de Sèze, 1988, Thrombosis research.

Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction.

C. Doutremépuich, M. Boisseau, R. Quilichini, 1983, Haemostasis.

[Role of the indirect fibrinolytic activity of heparins and similar compounds in the prevention of thrombosis].

C. Doutremépuich, F. Toulemonde, E. Vairel, 1983, Annales pharmaceutiques francaises.

Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits.

F. Bonini, C. Doutremépuich, F. Toulemonde, 1986, Thrombosis research.

Is there an optimal therapeutical range for low molecular weight heparin? An experimental study.

C. Doutremépuich, F. Doutremepuich, M. Lalanne, 1988, Thrombosis research.

[Duodenal absorption of a low molecular weight heparin in rabbits].

A. Massé, J. Lormeau, C. Doutremépuich, 1984, Pathologie-biologie.

Oral administration of low molecular weight heparin fractions in rabbits.

J. Lormeau, C. Doutremépuich, F. Toulemonde, 1985, Seminars in Thrombosis and Hemostasis.

Kinetic study of tPA release induced by heparin and heparin fragment.

C. Doutremépuich, E. Deharo, M. Lalanne, 1989, Thrombosis research.

[Thrombolytic action of heparin and a low molecular weight fraction].

A. Massé, C. Doutremépuich, F. Toulemonde, 1985, The´rapie (Paris).

Effects of aprotinin on heparin activities and heparin neutralization with protamine.

C. Doutremépuich, F. Azougagh Oualane, F. Toulemonde, 1992, Thrombosis research.

tPA‐Like Activity of an Experimental Thrombus in the Presence of Heparin and a Heparin Fraction

C. Doutremépuich, F. Toulemonde, O. Seze, 1989 .

Continuous arteriovenous hemofiltration with low-molecular-weight heparin.

B. Hory, F. Toulemonde, A. Cachoux, 1985, Nephron.